Lecanemab’s Path Forward: Navigating the Future of Alzheimer’s Treatment in Europe Amidst the EMA's Rejection

Abstract Lecanemab (Leqembi©, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer’s disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA) recently issued a negative opinion on its marketing auth...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandro Martorana, Chiara Giuseppina Bonomi, Martina Gaia Di Donna, Caterina Motta
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-11-01
Series:Neurology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40120-024-00675-w
Tags: Add Tag
No Tags, Be the first to tag this record!